Tulobuterol is a long-acting beta2-adrenergic receptor agonist, marketed in Japan as a transdermal patch under the name Hokunalin tape. Currently, it is only legal in 7 countries: Japan, Germany, China, South Korea, Bangladesh, Pakistan, and Venezuela. It provides sustained beta2 receptor stimulation via transdermal delivery to produce bronchodilation with reduced peak-trough plasma variability compared with short-acting inhaled agents. Pharmacologically, tulobuterol preferentially activates beta2 adrenoceptors on bronchial smooth muscle to increase cyclic AMP and promote airway smooth muscle relaxation; it is used for maintenance control of bronchospasm in obstructive airway disease. The transdermal formulation is designed for once-daily application and uses a matrix or reservoir adhesive to release drug across the stratum corneum, generating low steady-state plasma concentrations that limit systemic peak effects. Metabolism is primarily hepatic with common phase I oxidative and phase II conjugation pathways, and drug interactions reflect other agents that alter hepatic clearance or adrenergic tone. Standard quality control for the patch includes assay of active content, uniformity of dose, adhesive performance, and in vitro release testing to demonstrate consistent percutaneous flux.
Related substances observed during synthesis, storage, and metabolism include N-dealkylated amine derivatives, phenolic oxidation products, positional isomers and N-oxides; conjugated metabolites such as glucuronides appear in biological matrices. Typical analytical methods are reversed-phase HPLC with photodiode array detection and LC-MS for structural elucidation. Common specification ranges used by manufacturers and regulatory guidance set reporting and control thresholds based on ICH Q3A principles; in practice manufacturers commonly set individual related-compound limits in the range of 0.05 to 0.3 percent of the drug substance and total impurities limits in the range of 0.5 to 1.0 percent, with tighter limits applied for known toxic or genotoxic degradants and a typical assay acceptance window of about 98.0 to 102.0 percent for active content. Stability monitoring focuses on increases in oxidative and hydrolytic degradants under accelerated conditions and on transdermal product-specific attributes such as adhesive integrity and percutaneous release profile.
Tulobuterol is used as a bronchodilator for maintenance treatment of reversible airway obstruction, primarily to reduce bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease by stimulating beta2-adrenergic receptors to relax bronchial smooth muscle.
Apply the tulobuterol transdermal patch to a clean, dry, hairless area on the chest or upper back; avoid broken, irritated, or inflamed skin and areas over joints. Rotate application sites daily and follow the specific product instructions for adhesion time and site rotation.
Tulobuterol tape is the transdermal formulation used for once-daily maintenance bronchodilation; it delivers continuous low-level drug systemically to control baseline bronchospasm and reduce reliance on short-acting rescue inhalers in appropriate patients.
Tulobuterol is classified as a long-acting beta2-adrenergic receptor agonist and is grouped pharmacologically as a selective beta2 sympathomimetic bronchodilator.
